Zydus Lifesciences Limited
Promoter Group member Prashant Babubhai Patel acquired 32,577 shares of Zydus Lifesciences via transmission on August 19, 2026. This acquisition, categorized under Regulation 7 (2) filings, increased his holding from 0 to 32,577 shares. The shares were transferred from the estate of Late Jasodaben Babubhai Patel.
A vertically integrated pharmaceutical company, Zydus Lifesciences develops, manufactures, and markets generic drugs, specialty pharmaceuticals, and biologics for domestic and international markets. The company operates across multiple therapeutic areas including cardiology, gastroenterology, oncology, and immunology. It serves patients globally through its extensive distribution network, research capabilities, and commitment to addressing unmet healthcare needs across diverse populations and geographies.